The FDA alignment and debt conversion are transformative catalysts. Traders should watch for the Phase 3 protocol submission in Q3 2026 and potential partnership interest. The 34M share issuance is dilutive but removes a significant overhang.
Price Chart
Executive Summary
Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headline is the FDA alignment on the Phase 3 trial design for belapectin in MASH cirrhosis and the conversion of $105.8M in debt to equity by Chairman Uihlein, eliminating a major liability and strengthening the balance sheet.
Key Financial Metrics
Key Facts
- FDA alignment on key elements of planned Phase 3 trial for belapectin in MASH cirrhosis with portal hypertension; registrational protocol submission expected in Q3 2026.
- Chairman Richard E. Uihlein converted $105.8M in debt (principal + accrued interest) into 34,376,167 shares of common stock, eliminating the debt and simplifying the capital structure.
- Cash and cash equivalents of $13.2M as of June 30, 2026, plus $10M available under a line of credit; cash runway through June 2027.
- Net loss applicable to common stockholders increased to $9.2M ($0.14/share) from $7.6M ($0.12/share) in Q2 2025, primarily due to a $3.2M non-cash charge for change in fair value of derivative liabilities.
- R&D expenses decreased to $2.1M from $3.3M year-over-year; G&A expenses increased to $1.8M from $1.4M.
Financial Impact
Elimination of $105.8M in debt strengthens balance sheet; cash burn rate remains manageable with $13.2M cash plus $10M credit line.
Risk Factors
- Clinical trial risk: Phase 3 may fail to meet endpoints.
- Dilution: 34M new shares issued, increasing share count significantly.
- Need for additional capital beyond June 2027 if no partnership or revenue materializes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032946 |
| Document: ef20080011_8k.htm | 0001140361-26-032946 |
| Document: 0001140361-26-032946-index-headers.html | 0001140361-26-032946 |
| Document: 0001140361-26-032946-index.html | 0001140361-26-032946 |
| Document: 0001140361-26-032946.txt | 0001140361-26-032946 |
| 8-K Data (Synthetic) | 0001140361-26-032946 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.31 (−10.30%) |
Oct 13, 2026 14d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.31 (+10.30%) |
Oct 6, 2026 21d ago | Press Release | $3.76 | awaiting T+20 | — | $3.31 (−11.97%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.31 (−3.78%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.31 (−3.78%) |
Aug 4, 2026 12w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.31 (+10.70%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.31 (−23.56%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.31 (+52.53%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.31 (+52.53%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.31 (+40.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers